Vimeo
LinkedIn
Instagram
Share |

novartis

February 2, 2011

Swiss pharmaceutical giant Roche announced on 3 February that its full-year net profits rose by 11% year-on-year, despite putting into place a cost saving restructuring program.

Swiss pharmaceutical giant Roche announced on 3 February that its full-year net profits rose by 11% year-on-year, despite putting into place a cost saving restructuring program.

In a statement, the family-controlled company said that its profits increased in 2010 to 8.67 billion Swiss francs (€6.71 billion), from 7.78 billion francs the year before. However, its sales for the year reduced by 3%, attributed to the poor performance of its flu drug Tamiflu.

Click here >>
Close